ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Takeda Pharmaceutical Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 5.12%
- The company has been able to generate a Return on Capital Employed (avg) of 5.12% signifying low profitability per unit of total capital (equity and debt)
2
High Debt Company with a Debt to Equity ratio (avg) at times
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 4.36% signifying low profitability per unit of shareholders funds
3
Healthy long term growth as Net Sales has grown by an annual rate of 6.84% and Operating profit at 13.42%
4
The company declared very negative results in Mar'25 after flat results in Dec'24
- ROCE(HY) Lowest at 1.5%
- INVENTORY TURNOVER RATIO(HY) Lowest at 1.62 times
- INTEREST COVERAGE RATIO(Q) Lowest at 308.4
5
With ROCE of 4.85%, it has a very attractive valuation with a 0.99 Enterprise value to Capital Employed
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 24.74%, its profits have fallen by -46.4%
- At the current price, the company has a high dividend yield of 0
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Takeda Pharmaceutical Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Takeda Pharmaceutical Co., Ltd. for you?
Low Risk, High Return
Absolute
Risk Adjusted
Volatility
Takeda Pharmaceutical Co., Ltd.
24.74%
672.21
22.62%
Japan Nikkei 225
36.73%
1.30
28.24%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
6.84%
EBIT Growth (5y)
13.42%
EBIT to Interest (avg)
2.45
Debt to EBITDA (avg)
3.32
Net Debt to Equity (avg)
0.60
Sales to Capital Employed (avg)
0.37
Tax Ratio
37.38%
Dividend Payout Ratio
286.73%
Pledged Shares
0
Institutional Holding
0.05%
ROCE (avg)
5.23%
ROE (avg)
4.36%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
63
Industry P/E
Price to Book Value
0.98
EV to EBIT
20.38
EV to EBITDA
8.42
EV to Capital Employed
0.99
EV to Sales
2.39
PEG Ratio
NA
Dividend Yield
0.01%
ROCE (Latest)
4.85%
ROE (Latest)
1.56%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend13What is working for the Company
OPERATING CASH FLOW(Y)
Highest at JPY 1,089,991 MM
NET PROFIT(Q)
At JPY 103,639 MM has Grown at 286.79%
PRE-TAX PROFIT(Q)
At JPY 133,065 MM has Grown at 200.09%
RAW MATERIAL COST(Y)
Fallen by -5.24% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at 54.93 %
NET SALES(Q)
Highest at JPY 1,191,698 MM
OPERATING PROFIT(Q)
Highest at JPY 381,261 MM
-17What is not working for the Company
ROCE(HY)
Lowest at 1.5%
INVENTORY TURNOVER RATIO(HY)
Lowest at 1.62 times
INTEREST COVERAGE RATIO(Q)
Lowest at 308.4
INTEREST(Q)
Highest at JPY 123,627 MM
Here's what is working for Takeda Pharmaceutical Co., Ltd.
Net Profit
At JPY 103,639 MM has Grown at 286.79%
over average net sales of the previous four periods of JPY 26,794.5 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (JPY MM)
Operating Cash Flow
Highest at JPY 1,089,991 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (JPY MM)
Pre-Tax Profit
At JPY 133,065 MM has Grown at 200.09%
over average net sales of the previous four periods of JPY 44,342 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (JPY MM)
Net Sales
Highest at JPY 1,191,698 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (JPY MM)
Operating Profit
Highest at JPY 381,261 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (JPY MM)
Debt-Equity Ratio
Lowest at 54.93 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by -5.24% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Takeda Pharmaceutical Co., Ltd.
Interest
At JPY 123,627 MM has Grown at 48.7%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
Interest Coverage Ratio
Lowest at 308.4
in the last five periodsMOJO Watch
The company's ability to manage interest payments is deteriorating
Operating Profit to Interest
Inventory Turnover Ratio
Lowest at 1.62 times and Fallen
In each half year in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Interest
Highest at JPY 123,627 MM
in the last five periods and Increased by 48.7% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
